Review Article
Pharmacogenetic Approach for the Prevention of Rivaroxaban’s ADRs: A Systematic Review and Meta-Analysis
Table 1
Characteristics of included studies.
| Row | Author and year | Population | Provenance | Study design | Sample size | Age mean (SD) | Gender male (%) | Quality assessment |
| 1 | Campos-Staffico et al., 2022 [20] | Nonvalvular atrial fibrillation patients | United States | Retrospective cohort | 2364 | 68.3 (13.6) | 1606 (67.93) | 19 | 2 | Gouin-Thibault et al., 2016 [21] | Healthy male volunteers | France | Clinical trial | 60 | NR | 60 (100.00) | 21 | 3 | Lähteenmäki et al., 2021 [22] | Finnish rivaroxaban users | Finland | Retrospective cohort | 999 | 69.6 (9.8) | 501 (50.15) | 18 | 4 | Lenoir et al., 2022 [23] | Hospitalized rivaroxaban users | Switzerland | Prospective cohort | 125 | 71.7 (12.1) | 89 (71.20) | 18 | 5 | Nakagawa et al., 2017 [24] | Nonvalvular atrial fibrillation | Japan | Prospective cohort | 86 | 62.4 (10.6) | 73 (84.88) | 20 | 6 | Sychev et al., 2019 [25] | Patients undergoing total hip and knee replacement surgery | Russia (Moscow) | Prospective cohort | 78 | 59 (11) | 22 (28.20) | 19 | 7 | Sychev et al., 2022 [26] | Patients aged 80 years and older with nonvalvular atrial fibrillation | Russia (Moscow) | Cross-sectional | 128 | 87.5 | NR | 16 | 8 | Wang et al., 2021 [27] | Patients with atrial fibrillation | Mongolia | Retrospective cohort | 155 | 71.98 (10.72) | 81 (52.25) | 19 | 9 | Yoon et al., 2022 [28] | Patients receiving direct oral anticoagulants | Korea | Retrospective cohort | 576 | NR | 293 (50.86) | 19 | 10 | Zhang et al., 2023 [29] | Elderly patients with nonvalvular atrial fibrillation | Korea | Prospective cohort | 150 | 68 (12.8) | 63.33 | 17 |
|
|
NR, not reported; SD, standard deviation; quality assessment based on STROBE statement; quality assessment based on CONSORT statement. |